Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Sponsor
Yuhan Corporation
Study ID
NCT05862194
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lazertinib — DRUG
    Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
  • Platinum-based Chemotherapy — DRUG
    Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period

Study Details

This retrospective, external comparator study for Lazertinib aims to assess the real-world effectiveness of Lazertinib as the second-line treatment versus platinum-based chemotherapy in patients with epidermal growth receptor sensitizing mutation-positive, locally advanced or metastatic Non-small Lung cancer.

Key Dates

Start date
Jun 1, 2015
Status verified
Aug 2023
Primary completion
Apr 30, 2022
Completion
Mar 20, 2023

Study Design

Enrollment
534 participants (actual)

Arms

  • Arm: Lazertinib
  • Arm: Platinum-based Chemotherapy

Primary Outcome Measure

Comparative evaluation of (real-world:rw) Progression-free survival (PFS) between patients receiving Lazertinib versus Platinum-based Chemotherapy [ Time Frame: Up to 64 months ]

Related Studies